Señales en vivo de ELIC.ST | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 11:08):

Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden...

Stats
Volumen de hoy	72 443.00
Volumen promedio	99 931.00
Capitalización de mercado	18.40M
EPS	SEK-0.255 ( 2023-11-14 )
Próxima fecha de ganancias	( SEK0 ) 2024-05-16
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-1.120
ATR14	SEK0.0110 (1.18%)

Elicera Therapeutics AB Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Elicera Therapeutics AB Finanzas

Annual	2023
Ingresos:	SEK11.23M
Beneficio Bruto:	SEK11.22M (99.90 %)
EPS:	SEK-0.830

FY	2023
Ingresos:	SEK11.23M
Beneficio Bruto:	SEK11.22M (99.90 %)
EPS:	SEK-0.830

FY	2022
Ingresos:	SEK1.28M
Beneficio Bruto:	SEK1.27M (99.08 %)
EPS:	SEK-0.990

FY	2021
Ingresos:	SEK587.00
Beneficio Bruto:	SEK0.00 (0.00 %)
EPS:	SEK-0.663

Financial Reports:

No articles found.

Elicera Therapeutics AB

Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio of products in pipeline includes ELC-100, a Phase I/II drug candidate for neuroendocrine tumors indications; ELC-201, a preclinical drug candidate; ELC-301, a CAR T-cell therapy for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a preclinical drug candidate glioblastoma multiforme (brain tumor) indications. It also develops iTANK, a technology platform used to optimize the effect of all CAR T-cell therapies under the development and activate killer T-cells against cancer. The company was founded in 2014 and is based in Göteborg, Sweden.